Key Drivers
- Strong liquidity
- Zero revenues
- Persistent cash burn
AIAI Summary
GHRS has shifted from a speculative proof‑of‑concept to a well‑funded pivotal‑risk biotech where Phase 3 execution and reproducibility of the Phase 2b signal are the single largest value drivers—prioritize monitoring Phase 3 design, start/enrollment timelines, interim safety/efficacy readouts, and partnering/licensing that could extend runway. The key risk is a binary Phase 3 failure or cost/timing overruns that erode the cash buffer and trigger outsized downside versus the upside already priced into the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Zero revenues
- •Persistent cash burn
GHRS has a fortress-like balance sheet with $246M cash and almost no debt but faces zero revenue, large operating losses and cash burn while trading at a ~3.36x P/B premium.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Weak momentum
- •Mid-$15s cap
GHRS is in a mild short-term downtrend—price ~9% below the last-month SMA (~$15.36) with RSI ≈35, resistance around $15.30–$16.00 and immediate support near $14.00.
Price broke below the last-month
Sentiment & News
Key News Insights:
- •Strong cash runway
- •FDA clearance
- •Phase 3 planned
GH Research is well-funded ($280.7M), FDA-cleared to enroll U.S. subjects, and is advancing GH001 from positive Phase 2b results into a global pivotal Phase 3 to replicate rapid, durable antidepressant effects.
Adequate funding plus regulatory clearance materially de-risks near-term financing and positions the stock for upside if the pivotal Phase 3 confirms Phase 2b efficacy
Similar Companies in Healthcare
Other companies in the same sector with AI ratings